Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Multiple-Dose Study in Neovascular Age-related Macular Degeneration (nAMD) to Evaluate the Safety, Tolerability, Pharmacodynamics, Immunogenicity, and Clinical Effect of Repeat Intravitreal (IVT) Injections of GEM103 as an Adjunct to Standard of Care Aflibercept Therapy

NCT04684394 is registered in ClinicalTrials.gov with Gemini Therapeutics, Inc. as lead sponsor.

NCT NCT04684394
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04684394 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Multiple-Dose Study in Neovascular Age-related Macular Degeneration (nAMD) to Evaluate the Safety, Tolerability, Pharmacodynamics, Immunogenicity, and Clinical Effect of Repeat Intravitreal (IVT) Injections of GEM103 as an Adjunct to Standard of Care Aflibercept Therapy
Lead sponsor
Gemini Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
December 29, 2020
Completion date
February 18, 2022
Enrollment
50 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

macular degeneration, neovascular age-related macular degeneration, retinal degeneration, retinal disease